SIGA Technologies, Inc. (SIGA)
NASDAQ: SIGA · Real-Time Price · USD
5.91
-0.12 (-1.99%)
At close: Dec 20, 2024, 4:00 PM
5.89
-0.02 (-0.34%)
After-hours: Dec 20, 2024, 5:07 PM EST
SIGA Technologies Revenue
SIGA Technologies had revenue of $10.01M in the quarter ending September 30, 2024, with 8.39% growth. This brings the company's revenue in the last twelve months to $173.73M, up 399.31% year-over-year. In the year 2023, SIGA Technologies had annual revenue of $139.92M with 26.31% growth.
Revenue (ttm)
$173.73M
Revenue Growth
+399.31%
P/S Ratio
2.42
Revenue / Employee
$3,860,697
Employees
45
Market Cap
422.00M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 139.92M | 29.14M | 26.31% |
Dec 31, 2022 | 110.78M | -22.89M | -17.13% |
Dec 31, 2021 | 133.67M | 8.71M | 6.97% |
Dec 31, 2020 | 124.96M | 98.22M | 367.28% |
Dec 31, 2019 | 26.74M | -450.31M | -94.39% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Emergent BioSolutions | 1.13B |
DocGo | 694.97M |
Health Catalyst | 302.06M |
Esperion Therapeutics | 295.45M |
Treace Medical Concepts | 202.86M |
MaxCyte | 45.60M |
Verve Therapeutics | 24.40M |
SIGA News
- 11 days ago - Interim Results from STOMP Study of SIGA's Tecovirimat in Treatment of Mpox Announced - GlobeNewsWire
- 19 days ago - SIGA Technologies Vs Emergent BioSolutions: Product Portfolio And Future Outlook - Seeking Alpha
- 4 weeks ago - SIGA Technologies: Expansion Into mAbs Is Smart, But Eggs Remain In One Basket - Seeking Alpha
- 6 weeks ago - SIGA Technologies (SIGA) Shares Tumble After Mpox Therapy Fails, Chief Medical Officer Terminated - Hagens Berman - GlobeNewsWire
- 6 weeks ago - SIGA Technologies, Inc. (SIGA) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 7 weeks ago - SIGA to Host Business Update Call on November 7 Following Release of Third-Quarter 2024 Financial Results - GlobeNewsWire
- 2 months ago - Wolf Haldenstein Adler Freeman & Herz LLP announces that it is investigating SIGA Technologies, Inc. for potential violations of federal securities laws - PRNewsWire
- 2 months ago - SIGA Enters into Exclusive License Agreement with Vanderbilt University for Novel Poxvirus Monoclonal Antibodies - GlobeNewsWire